rss
Gut doi:10.1136/gutjnl-2012-303735
  • Inflammatory bowel disease
  • Original article

Amniotic fluid stem cells improve survival and enhance repair of damaged intestine in necrotising enterocolitis via a COX-2 dependent mechanism

  1. Paolo De Coppi1
  1. 1Surgery Unit, University College London Institute of Child Health, London, UK
  2. 2Department of Histopathology, Great Ormond Street Hospital for Children, London, UK
  3. 3Research & Innovation S.p.A., Padova, Italy
  4. 4Laboratory of Oncohematology, Department of Pediatrics, University of Padova, and Fondazione Città della Speranza, Padova, Italy
  5. 5Wake Forest Institute for Regenerative Medicine, Wake Forest University School of Medicine, Medical Center Blvd, Winston-Salem, North Carolina, USA
  6. 6Division of Medicine, UCL Centre for Advanced Biomedical Imaging, Institute of Child Health, University College London, London, UK
  1. Correspondence to Dr Paolo De Coppi and Dr Simon Eaton, Surgery Unit, University College London Institute of Child Health, 30 Guilford Street, London WC1N 1EH, UK; p.decoppi{at}ucl.ac.uk and s.eaton{at}ucl.ac.uk
  • Received 30 October 2012
  • Revised 25 January 2013
  • Accepted 1 March 2013
  • Published Online First 24 March 2013

Abstract

Objective Necrotising enterocolitis (NEC) remains one of the primary causes of morbidity and mortality in neonates and alternative strategies are needed. Stem cells have become a therapeutic option for other intestinal diseases, which share some features with NEC. We tested the hypothesis that amniotic fluid stem (AFS) cells exerted a beneficial effect in a neonatal rat model of NEC.

Design Rats intraperitoneally injected with AFS cells and their controls (bone marrow mesenchymal stem cells, myoblast) were analysed for survival, behaviour, bowel imaging (MRI scan), histology, bowel absorption and motility, immunofluorescence for AFS cell detection, degree of gut inflammation (myeloperoxidase and malondialdehyde), and enterocyte apoptosis and proliferation.

Results AFS cells integrated in the bowel wall and improved rat survival and clinical conditions, decreased NEC incidence and macroscopic gut damage, improved intestinal function, decreased bowel inflammation, increased enterocyte proliferation and reduced apoptosis. The beneficial effect was achieved via modulation of stromal cells expressing cyclooxygenase 2 in the lamina propria, as shown by survival studies using selective and non-selective cyclooxygenase 2 inhibitors. Interestingly, AFS cells differentially expressed genes of the Wnt/β-catenin pathway, which regulate intestinal epithelial stem cell function and cell migration and growth factors known to maintain gut epithelial integrity and reduce mucosal injury.

Conclusions We demonstrated here for the first time that AFS cells injected in an established model of NEC improve survival, clinical status, gut structure and function. Understanding the mechanism of this effect may help us to develop new cellular or pharmacological therapies for infants with NEC.


Free sample
This recent issue is free to all users to allow everyone the opportunity to see the full scope and typical content of Gut.
View free sample issue >>

Don't forget to sign up for content alerts so you keep up to date with all the articles as they are published.

Navigate This Article